<p>Certara（納斯達克代碼：CERT - 獲取免費報告）在週六發佈給客户和投資者的研究報告中，被華爾街 Zen 的股票分析師將評級從 “持有” 上調至 “買入”。</p>
<ul>
<li>3 只可能在市場波動後飆升的動量股</li>
</ul>
<p>其他一些券商也對 CERT 發表了看法。KeyCorp 將 Certara 的目標價從 13.00 美元下調至 12.00 美元，並在 1 月 8 日的報告中對該股票給予 “增持” 評級。Stephens 將 Certara 的目標價從 15.00 美元下調至 12.00 美元，並在 12 月 12 日的研究報告中對該股票給予 “增持” 評級。Leerink Partners 將 Certara 的評級從 “市場表現” 上調至 “跑贏大盤”，並在 1 月 6 日的研究報告中為該公司設定了 13.00 美元的目標價。摩根士丹利將 Certara 的目標價從 16.00 美元下調至 12.00 美元，並在 12 月 18 日的報告中對該股票給予 “持平” 評級。最後，巴克萊將 Certara 的目標價從 14.00 美元下調至 13.00 美元，並在 12 月 15 日的研究報告中對該公司給予 “增持” 評級。一位股票研究分析師對該股票給予了強烈買入評級，七位給予了買入評級，六位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 12.82 美元。</p>
<p><strong>閲讀我們關於 Certara 的最新報告</strong></p>
<h2>Certara 價格表現</h2>
<ul>
<li>儘管每股收益超出預期，Simulations Plus 股票下跌 15%</li>
</ul>
<p>CERT 股票在週五開盤價為 7.23 美元。該公司的 50 日移動平均線為 9.06 美元，200 日移動平均線為 10.28 美元。公司的債務與股本比率為 0.27，流動比率為 2.09，速動比率為 2.09。該公司的市值為 11.5 億美元，市盈率為 103.29，貝塔值為 1.47。Certara 的 1 年最低價為 7.16 美元，1 年最高價為 15.69 美元。</p>
<p>Certara（納斯達克代碼：CERT - 獲取免費報告）最後一次公佈季度財報是在 11 月 6 日。該公司報告季度每股收益為 0.14 美元，超出分析師一致預期的 0.11 美元，超出幅度為 0.03 美元。該季度的營業收入為 1.0462 億美元，而一致預期為 1.0453 億美元。Certara 的股本回報率為 5.18%，淨利潤率為 2.62%。在去年同期，該公司每股收益為 0.13 美元。分析師預計 Certara 在當前財政年度的每股收益將達到 0.28 美元。</p>
<h2>機構資金流入和流出</h2>
<ul>
<li>這 3 只小型動量股是否正在醖釀大幅上漲？</li>
</ul>
<p>機構投資者最近買入和賣出了該公司的股票。First Horizon Corp 在第三季度收購了 Certara 的新股份，價值約 30,000 美元。Versant Capital Management Inc 在第三季度將其在 Certara 的持倉提高了 66.7%。Versant Capital Management Inc 現在擁有 2,881 股該公司的股票，價值 35,000 美元，此前在此期間又收購了 1,153 股。Osaic Holdings Inc.在第二季度將其在 Certara 的持倉提高了 50.7%。Osaic Holdings Inc.現在擁有 3,491 股該公司的股票，價值 41,000 美元，此前在此期間又收購了 1,175 股。Elevation Point Wealth Partners LLC 在第二季度購買了 Certara 的新股份，價值約 59,000 美元。最後，Global Retirement Partners LLC 在第三季度將其在 Certara 的持倉增加了 45.0%。Global Retirement Partners LLC 現在擁有 5,636 股該公司的股票，價值 69,000 美元，此前在此期間又購買了 1,749 股。當前 73.96% 的股票由機構投資者和對沖基金持有。</p>
<h2>Certara 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Certara 是一家生物模擬軟件和服務公司，與製藥、生物技術和醫療器械開發商合作，加速藥物發現、開發和監管審批。該公司的平台整合了定量藥理學、真實世界證據、人工智能和機器學習，以模擬和模擬藥物在多種治療領域和患者羣體中的行為。通過應用這些機制和數據驅動的方法，Certara 幫助客户預測臨牀結果，優化給藥策略，並在產品生命週期內簡化決策過程。</p>
<p>該公司的產品分為軟件工具和諮詢服務。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Certara 更好</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>黃金市場崩潰的那一天</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>你的銀行賬户不再安全</li>
<li>他剛剛準確預測了另一個黃金走勢……</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VSVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VSVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Certara 嗎？</h2>
<p>在考慮 Certara 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Certara 並不在名單上。</p>
<p>雖然 Certara 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CERT

<p>華爾街禪將 Certara（NASDAQ:CERT）的評級從 “持有” 上調至 “買入”。其他券商也調整了他們的目標價，KeyCorp 將其下調至 12.00 美元，Stephens 也下調至 12.00 美元，而 Leerink Partners 則設定為 13.00 美元。Certara 的股票開盤價為 7.23 美元，市值為 11.5 億美元，市盈率為 103.29。該公司報告上個季度每股收益為 0.14 美元，超出預期。機構投資者持有該股票的 73.96%，該公司專注於藥物開發的生物仿真軟件</p>

<p>Certara (NASDAQ:CERT - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report issued to clients and investors on Saturday.</p>
<div class="lb-trans"><p>Certara（納斯達克代碼：CERT - 獲取免費報告）在週六發佈給客户和投資者的研究報告中，被華爾街 Zen 的股票分析師將評級從 “持有” 上調至 “買入”。</p>
</div><ul>
<li>3 Momentum Stocks That Could Soar Post-Market Volatility</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只可能在市場波動後飆升的動量股</li>
</ul>
</div><p>A number of other brokerages have also weighed in on CERT. KeyCorp reduced their price objective on shares of Certara from $13.00 to $12.00 and set an &#34;overweight&#34; rating on the stock in a report on Thursday, January 8th. Stephens cut their price target on Certara from $15.00 to $12.00 and set an &#34;overweight&#34; rating on the stock in a research note on Friday, December 12th. Leerink Partners raised Certara from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $13.00 price objective for the company in a research report on Tuesday, January 6th. Morgan Stanley dropped their price objective on Certara from $16.00 to $12.00 and set an &#34;equal weight&#34; rating on the stock in a report on Thursday, December 18th. Finally, Barclays decreased their target price on Certara from $14.00 to $13.00 and set an &#34;overweight&#34; rating for the company in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $12.82.</p>
<div class="lb-trans"><p>其他一些券商也對 CERT 發表了看法。KeyCorp 將 Certara 的目標價從 13.00 美元下調至 12.00 美元，並在 1 月 8 日的報告中對該股票給予 “增持” 評級。Stephens 將 Certara 的目標價從 15.00 美元下調至 12.00 美元，並在 12 月 12 日的研究報告中對該股票給予 “增持” 評級。Leerink Partners 將 Certara 的評級從 “市場表現” 上調至 “跑贏大盤”，並在 1 月 6 日的研究報告中為該公司設定了 13.00 美元的目標價。摩根士丹利將 Certara 的目標價從 16.00 美元下調至 12.00 美元，並在 12 月 18 日的報告中對該股票給予 “持平” 評級。最後，巴克萊將 Certara 的目標價從 14.00 美元下調至 13.00 美元，並在 12 月 15 日的研究報告中對該公司給予 “增持” 評級。一位股票研究分析師對該股票給予了強烈買入評級，七位給予了買入評級，六位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 12.82 美元。</p>
</div><p><strong>Read Our Latest Report on Certara</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Certara 的最新報告</strong></p>
</div><h2>Certara Price Performance</h2>
<div class="lb-trans"><h2>Certara 價格表現</h2>
</div><ul>
<li>Simulations Plus Stock Drops 15% Despite EPS Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>儘管每股收益超出預期，Simulations Plus 股票下跌 15%</li>
</ul>
</div><p>CERT stock opened at $7.23 on Friday. The business's 50-day moving average is $9.06 and its two-hundred day moving average is $10.28. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The firm has a market capitalization of $1.15 billion, a P/E ratio of 103.29 and a beta of 1.47. Certara has a 1 year low of $7.16 and a 1 year high of $15.69.</p>
<div class="lb-trans"><p>CERT 股票在週五開盤價為 7.23 美元。該公司的 50 日移動平均線為 9.06 美元，200 日移動平均線為 10.28 美元。公司的債務與股本比率為 0.27，流動比率為 2.09，速動比率為 2.09。該公司的市值為 11.5 億美元，市盈率為 103.29，貝塔值為 1.47。Certara 的 1 年最低價為 7.16 美元，1 年最高價為 15.69 美元。</p>
</div><p>Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.03. The business had revenue of $104.62 million during the quarter, compared to the consensus estimate of $104.53 million. Certara had a return on equity of 5.18% and a net margin of 2.62%.During the same period in the previous year, the company posted $0.13 earnings per share. Analysts anticipate that Certara will post 0.28 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Certara（納斯達克代碼：CERT - 獲取免費報告）最後一次公佈季度財報是在 11 月 6 日。該公司報告季度每股收益為 0.14 美元，超出分析師一致預期的 0.11 美元，超出幅度為 0.03 美元。該季度的營業收入為 1.0462 億美元，而一致預期為 1.0453 億美元。Certara 的股本回報率為 5.18%，淨利潤率為 2.62%。在去年同期，該公司每股收益為 0.13 美元。分析師預計 Certara 在當前財政年度的每股收益將達到 0.28 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><ul>
<li>Are These 3 Small Momentum Stocks Setting Up Big Gains?</li>
</ul>
<div class="lb-trans"><ul>
<li>這 3 只小型動量股是否正在醖釀大幅上漲？</li>
</ul>
</div><p>Institutional investors have recently bought and sold shares of the business. First Horizon Corp acquired a new stake in shares of Certara during the third quarter worth about $30,000. Versant Capital Management Inc lifted its position in Certara by 66.7% during the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company's stock worth $35,000 after acquiring an additional 1,153 shares during the period. Osaic Holdings Inc. lifted its position in Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company's stock worth $41,000 after acquiring an additional 1,175 shares during the period. Elevation Point Wealth Partners LLC purchased a new position in shares of Certara in the 2nd quarter valued at approximately $59,000. Finally, Global Retirement Partners LLC increased its holdings in shares of Certara by 45.0% in the third quarter. Global Retirement Partners LLC now owns 5,636 shares of the company's stock valued at $69,000 after purchasing an additional 1,749 shares during the period. 73.96% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>機構投資者最近買入和賣出了該公司的股票。First Horizon Corp 在第三季度收購了 Certara 的新股份，價值約 30,000 美元。Versant Capital Management Inc 在第三季度將其在 Certara 的持倉提高了 66.7%。Versant Capital Management Inc 現在擁有 2,881 股該公司的股票，價值 35,000 美元，此前在此期間又收購了 1,153 股。Osaic Holdings Inc.在第二季度將其在 Certara 的持倉提高了 50.7%。Osaic Holdings Inc.現在擁有 3,491 股該公司的股票，價值 41,000 美元，此前在此期間又收購了 1,175 股。Elevation Point Wealth Partners LLC 在第二季度購買了 Certara 的新股份，價值約 59,000 美元。最後，Global Retirement Partners LLC 在第三季度將其在 Certara 的持倉增加了 45.0%。Global Retirement Partners LLC 現在擁有 5,636 股該公司的股票，價值 69,000 美元，此前在此期間又購買了 1,749 股。當前 73.96% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Certara Company Profile</h2>
<div class="lb-trans"><h2>Certara 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company's platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.</p>
<div class="lb-trans"><p>Certara 是一家生物模擬軟件和服務公司，與製藥、生物技術和醫療器械開發商合作，加速藥物發現、開發和監管審批。該公司的平台整合了定量藥理學、真實世界證據、人工智能和機器學習，以模擬和模擬藥物在多種治療領域和患者羣體中的行為。通過應用這些機制和數據驅動的方法，Certara 幫助客户預測臨牀結果，優化給藥策略，並在產品生命週期內簡化決策過程。</p>
</div><p>The company's offerings are divided into software tools and consulting services.</p>
<div class="lb-trans"><p>該公司的產品分為軟件工具和諮詢服務。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Certara</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The day the gold market broke</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>He just nailed another gold prediction …</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Certara 更好</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>黃金市場崩潰的那一天</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>你的銀行賬户不再安全</li>
<li>他剛剛準確預測了另一個黃金走勢……</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VSVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=CERT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Certara Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Certara 嗎？</h2>
</div><p>Before you consider Certara, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Certara 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Certara 並不在名單上。</p>
</div><p>While Certara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Certara 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Certara（納斯達克股票代碼：CERT）在 Wall Street Zen 被上調至買入評級